Bristol Myers Squibb Adds Mirati Therapeutics to Its Oncology Portfolio – Merger Arbitrage Mondays
Key Highlights
- The acquisition of Mirati Therapeutics (MRTX) by Bristol-Myers Squibb Company (BMY) for $5.8 billion equity value including the value of a CVR worth as estimated $1 billion.
- Amgen (AMGN) completes the acquisition of Horizon Therapeutics Public Limited Company (HZNP).
- Sen. Elizabeth Warren (D-MA) and Rep. Pramila Jayapal (D-WA) asks antitrust regulators to examine UnitedHealth Group’s (UNH) planned purchase of Amedisys (AMED).
Mirati Therapeutics (MRTX) $60.20
Market Cap: $4.11 billion
Enterprise Value: $3.38 billion
Oncology company Mirati Therapeutics has been a potential M&A target for several years.
Only plus or premium subscribers can access this post. Subscribe today.
